Fund moves
78KShares reported
From a 13F filed Nov 16, 2026 covering holdings at Sep 30, 2026 — a quarter-end snapshot, not a live trade.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
BMY · NYSE · Pharmaceuticals
Bristol Myers Squibb (BMY) · oqro.io/stocks/BMY · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
Baskets of the companies that insiders, members of Congress or funds recently reported buying, each held under a written rule.
$59.56−1.79 (−2.92%)
Close of Nov 18, 2026, vs Nov 17 · end-of-day, not a live quote
No open-market purchase by an insider of Bristol Myers Squibb was filed in the last 90 days. The latest on record was on Apr 29, 2025.
Since 2006, Bristol Myers Squibb insiders reported 47 open-market purchases and 404 sales on Forms 4 and 5, with purchases in 10 different years, most recently 2025.
In the last 90 days, 3 insiders of Bristol Myers Squibb (BMY) reported 3 open-market sales worth $678K in total on SEC Form 4. The largest seller by value was Cristian Massacesi, with $403K. Many insider sales follow a plan set in advance or cover taxes on stock awards; the filing says what was sold, not the reason.
Yes. Members of Congress disclosed 9 trades in Bristol Myers Squibb (BMY) in the last 12 months, each reported as a value range on a periodic transaction report. The most recent are from Sen. Alan Armstrong, Rep. Mike Kelly (PA16), Rep. Julie Johnson (TX32) and 2 other members.
Bristol Myers Squibb's next results are expected on Feb 3, 2027, after the market closes. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
+26.6% (+$12.50) from Nov 18, 2025 to Nov 18, 2026 · adjusted daily closes
Adjusted close went from $47.06 on Nov 18, 2025 to $59.56 on Nov 18, 2026 (+26.6%). Disclosed in this range: 3 insider trades, 2 pre-arranged insider sales, 4 Congress trades, and 129 13F position changes for 4 quarters ending in it.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Pharmaceuticals company based in New York City, New York.
Last 12 months
+26.6%
Market value
$122B
S&P 500 +10.6% over the same dates. Prices adjusted for splits and dividends.
Short interest: 46.8M shares sold short (2.3% of shares outstanding), −6.2% vs the previous count, 4.2 days of normal trading to buy them back. FINRA, as of Oct 30, 2026.
Revenue
$13.1B
+6.9% vs the same quarter a year earlier
Free cash flow, last 12 months
$9.29B
This quarter $3.84B, a year earlier $5.99B
Net debt
$33B
Debt $42.6B, cash $9.57B, at Sep 30, 2026
Net income, last 12 months
$9.24B
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Oct 29, 2026.
Revenue, fiscal 2025
$48.2B
−0.2% vs the year before
Net income, fiscal 2025
$7.05B
As reported in the annual filing
Shares outstanding
2.04B
As of Oct 21, 2026
In fiscal 2025 the company spent $5.04B on dividends. Cash actually paid, from its cash-flow statement.
Fund moves
From a 13F filed Nov 16, 2026 covering holdings at Sep 30, 2026 — a quarter-end snapshot, not a live trade.
Insider selling
Traded Nov 5 · filed 1 day laterNot reported under a pre-arranged trading plan
Since the trade −5.7% · S&P 500 −0.4% · to Nov 18
A Bristol Myers Squibb director sold $241K of Bristol Myers Squibb shares. The filing does not indicate a pre-arranged trading plan.
Insider selling
Traded Nov 5 · filed the same day
A Bristol Myers Squibb director told the SEC about a plan to sell $250K of Bristol Myers Squibb shares around Nov 5, 2026. The shares were not acquired as compensation.
Insider selling
Traded Sep 9 · filed 1 day laterNot reported under a pre-arranged trading plan
Since the trade −7.5% · S&P 500 −4.2% · to Nov 18
Bristol Myers Squibb's Chief Med Offr,Head of Dev sold $403K of Bristol Myers Squibb shares. The filing does not indicate a pre-arranged trading plan.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Insiders of Bristol Myers Squibb reported 47 open-market purchases and 404 sales since 2006; purchases in 10 different years, most recently 2025.
| Year | Bought | Sold |
|---|---|---|
| 2026 | — | $2.53M5×5 trades |
| 2025 | $412K3×3 trades | $2.67M3×3 trades |
| 2024 | $100K1×1 trade | $39K1×1 trade |
| 2023 | $673K3×3 trades | $23.3M5×5 trades |
| 2022 | — | $40.1M15×15 trades |
| 2021 | — | $34.7M20×20 trades |
| 2020 | $500K1×1 trade | $25.3M13×13 trades |
| 2019 | $734K3×3 trades | $2.51M4×4 trades |
| 2018 | $750K2×2 trades | — |
| 2017 | $1.27M3×3 trades | $21.4M11×11 trades |
| 2016 | — | $50.1M44×44 trades |
| 2015 | — | $48.9M36×36 trades |
| 2014 | — | $65.1M40×40 trades |
| 2013 | — | $109M84×84 trades |
| 2012 | — | $37.2M81×81 trades |
| 2011 | $23K1×1 trade | $20.9M12×12 trades |
| 2010 | — | $13.7M15×15 trades |
| 2009 | $769K2×2 trades | $184K11×11 trades |
| 2008 | $2.39M28×28 trades | — |
| 2006 | — | $535K4×4 trades |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
On the public record for Bristol Myers Squibb over the 12 months to Nov 18, 2026: 2 FDA records, 24 executive contributions and 95 clinical trials (7th most among listed companies).
Vanguard Capital Management
Schedule 13G: passive · filed Apr 29, 2026 · 153M shares
STATE STREET CORPORATION
Schedule 13G: passive · filed Aug 7, 2026 · 103M shares
Anyone owning more than 5% must file within days. Structured filings have existed since December 2024, so older stakes that were never amended may be missing.
Federal rules, proposed rules and notices that name the company by its legal name, from the Federal Register. Being named is not the same as being the target of a rule.
Against the S&P 500 over the year
Since Nov 14, 2025, BMY is up 31.5% and the index fund is up 9.0%: 23 points ahead of the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much BMY moves
End-of-day prices. These figures describe the past year and say nothing about what comes next.
3 approvals or clearances and 0 recalls recorded by the FDA for this company and its listed subsidiaries.
From openFDA: Drugs@FDA (new applications and new uses), device 510(k) and PMA decisions, and FDA enforcement reports. Class I recalls are the most serious, Class III the least. Most recalls are started by the company itself. Labeling and manufacturing changes are not listed.
66 active phase 3 trials and 35 active phase 2 trials led by this company, mostly in melanoma, alzheimer disease, schizophrenia. The ones with the nearest registered primary completion date still ahead:
27 trials have a registered primary completion date that has already passed. That usually means the data are being analyzed, or the entry has not been updated.
Source: ClinicalTrials.gov, studies whose lead sponsor is the company or a listed subsidiary. “Primary completion” is the sponsor's own registry date for the last main data collection. It is not an approval date, it says nothing about the result, and it is often revised.
1 notice filed with state agencies, covering 133 workers in total. Employers must warn the state ahead of a plant closing or mass layoff at a site.
Official WARN lists from California, Texas, New York, Florida, Illinois and Washington only; notices filed in other states are not shown. Matched on the employer name as filed, so a notice filed under an unrelated subsidiary name can be missing. Dates are the notice date (Washington: the date the state received it).
124 certified in FY2026 Q3, vs 130 a year earlier. 124 positions in total, median offered wage $155K a year.
Labor condition applications for H-1B workers certified by the Department of Labor, counted by decision date (FY2026 Q3: Apr 1, 2026 to Jun 30, 2026, the latest quarter published). A certified application is a step before a visa petition, not a hire or a visa, and one application can cover several positions. Matched by employer ID number or name.
Short sale volume: 45.4% of the volume reported to FINRA over the last 20 trading days was marked short, below its 1-year average of 48.3%. FINRA daily files, to Nov 18, 2026.
Fails to deliver: 42K shares (about $2.66M) were not delivered on time for settlement on Oct 23, 2026. SEC fails-to-deliver data.
Short sale volume is not short interest. It counts trades marked short, including market makers selling short to fill buy orders, so it is a share of daily trading, not a count of bets against the stock. Fails to deliver have many causes, including processing delays, and are often resolved within days.
Last results
Oct 29, 2026
Within the 30 days after it, until Nov 28, 2026
Next results, expected
Feb 3, 2027
after the market closes; the date can move until the company confirms it
Purchases after results
64%
7 of 11 insider purchases since 2019 came within 30 days after a results announcement
From Bristol Myers Squibb's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Bristol Myers Squibb's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.